JHVEPhoto / Shutterstock.com
2 September 2022AmericasStaff Writer
Novo Nordisk makes $1.1bn bid for biopharma company
Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Generics
24 March 2022 Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza before the companies were meant to face trial in April.
Americas
9 August 2022 Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.
Big Pharma
2 November 2022 Cardiovascular ‘innovator’ snapped up as company strengthens medtech offering | Massachusetts-based Abiomed will become part of purchaser’s medtech division
Editor's picks
Editor's picks
Generics
24 March 2022 Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza before the companies were meant to face trial in April.
Americas
9 August 2022 Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.
Big Pharma
2 November 2022 Cardiovascular ‘innovator’ snapped up as company strengthens medtech offering | Massachusetts-based Abiomed will become part of purchaser’s medtech division
Generics
24 March 2022 Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza before the companies were meant to face trial in April.
Americas
9 August 2022 Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.
Big Pharma
2 November 2022 Cardiovascular ‘innovator’ snapped up as company strengthens medtech offering | Massachusetts-based Abiomed will become part of purchaser’s medtech division